BiomX PHGE

NYSE PHGE

$1.67 +0.12 (+7.74%)

As of: Sep 9, 2026 · 3:59 PM EDT

Key Stats

Market Cap17.33 Mn

P/E0.65

P/S4.66

Div. Yield0.00

Total Debt (Qtr)1.71 Mn

Add ratio to table…

About

BiomX Inc. is a clinical stage product discovery company developing natural and engineered phage based therapies to target and kill specific harmful bacteria associated with chronic diseases such as diabetic foot infections. The company uses its proprietary research and development platform to screen identify and combine phage strains that can penetrate biofilms resist resistance and remain stable for manufacturing. Its product candidates are designed to treat conditions…

BiomX Inc. has not generated any revenue from product sales because all of its candidates remain in clinical development. The company funds its operations through government grants such as the $5.8 million received from the Medical Technology Enterprise Consortium and through private placements including the December 2025 sale of Series Y Convertible Preferred Stock and warrants for gross proceeds of $3.0 million. These financing activities support ongoing research and limited operational activities while the company evaluates strategic alternatives.

BiomX Inc. operates in the highly competitive biotechnology sector focused on phage therapy where it faces rivals such as Locus Biosciences Armata Pharmaceuticals and SNIPR Biome as well as academic programs and larger pharmaceutical companies with greater resources. Its competitive advantages stem from a proprietary phage discovery platform that integrates computational biology microbiology synthetic engineering and high throughput screening to produce optimized phage cocktails or personalized treatments. The company also benefits from collaborations with institutions such as the Walter Reed Army Institute of Research and the National Institutes of Health which provide access to phage libraries and clinical trial support.

The company serves patients suffering from bacterial infections linked to chronic diseases including individuals with diabetic foot infections diabetic foot osteomyelitis and potentially those with cystic fibrosis or atopic dermatitis. Its therapies are intended for use in hospital settings under the supervision of healthcare providers and are being evaluated in clinical trials that enroll adult patients with specific bacterial strains identified through diagnostic testing.

Investment Thesis

▲ Bull case

BiomX is undergoing a strategic and financial reset under new leadership that prioritizes capital efficiency and operational discipline, which could unlock hidden value by resolving the overhang from long-dated warrants and reducing structural impediments to investor confidence. The amendment of the December 2025 investment warrants to a one-year exercise period at $1.00 per share significantly reduces their theoretical dilution impact and clears a near-term uncertainty that has likely been weighing on the stock, making the capital structure more transparent and attractive to institutional investors who may have been deterred by complex or long-term dilution risks. This move, combined with the CEO’s explicit focus on simplifying the capital structure and strengthening engagement with investment banks and institutional investors, suggests a deliberate effort to improve market accessibility and liquidity, which could lead to a re-rating of the stock as perceived risk decreases. Furthermore, the new leadership team brings deep experience from capital-intensive and defense-related sectors—Oster from energy and aerospace-adjacent industries, Rokach from finance and public company management—providing BiomX with enhanced credibility in navigating complex corporate transactions and capital markets, skills that are directly applicable as the company evaluates strategic repositioning toward high-demand sectors like defense applications. This expertise increases the likelihood of successful execution on non-core opportunities that could diversify revenue streams and reduce reliance on the volatile phage therapy development timeline, offering a potential near-term catalyst beyond the traditional biotech milestones. The active evaluation of repositioning toward sectors benefiting from strong global demand for advanced technologies, coupled with cost-cutting measures like finalizing Maryland facility closure expenses, indicates a pragmatic shift toward sustainability and financial resilience, which may allow BiomX to extend its cash runway while pursuing value-accretive strategic alternatives, a move that is often undervalued by markets focused solely on clinical trial outcomes.

BiomX is undergoing a strategic and financial reset under new leadership that prioritizes capital efficiency and operational discipline, which could unlock hidden value by resolving the overhang from long-dated warrants and reducing structural impediments to investor confidence. The amendment of the December 2025 investment warrants to a one-year exercise period at $1.00 per share significantly reduces their theoretical dilution impact and clears a near-term uncertainty that has likely been weighing on the stock, making the capital structure more transparent and attractive to institutional investors who may have been deterred by complex or long-term dilution risks. This move, combined with the CEO’s explicit focus on simplifying the capital structure and strengthening engagement with investment banks and institutional investors, suggests a deliberate effort to improve market accessibility and liquidity, which could lead to a re-rating of the stock as perceived risk decreases. Furthermore, the new leadership team brings deep experience from capital-intensive and defense-related sectors—Oster from energy and aerospace-adjacent industries, Rokach from finance and public company management—providing BiomX with enhanced credibility in navigating complex corporate transactions and capital markets, skills that are directly applicable as the company evaluates strategic repositioning toward high-demand sectors like defense applications. This expertise increases the likelihood of successful execution on non-core opportunities that could diversify revenue streams and reduce reliance on the volatile phage therapy development timeline, offering a potential near-term catalyst beyond the traditional biotech milestones. The active evaluation of repositioning toward sectors benefiting from strong global demand for advanced technologies, coupled with cost-cutting measures like finalizing Maryland facility closure expenses, indicates a pragmatic shift toward sustainability and financial resilience, which may allow BiomX to extend its cash runway while pursuing value-accretive strategic alternatives, a move that is often undervalued by markets focused solely on clinical trial outcomes.

▼ Bear case

Despite the leadership changes and financial restructuring efforts, BiomX remains a clinical-stage company with no revenue-generating products, and the recent news provides no evidence of clinical progress, partnership advancements, or near-term milestones in its core phage therapy pipeline, meaning the company’s fundamental value still hinges on uncertain and long-distant binary outcomes from clinical trials that are highly susceptible to failure, delays, or regulatory setbacks. The emphasis on evaluating strategic opportunities in defense-related applications and engaging with Wall Street advisors suggests a potential distraction from or lack of confidence in the core business, raising concerns that management may be pivoting away from its stated mission due to insufficient progress in phage therapy development, which could signal underlying weaknesses in the BOLT platform or target validation that are not being disclosed. While the warrant amendment reduces theoretical overhang, it does not address the company’s ongoing cash burn or lack of funding visibility, and the reliance on cost-cutting measures like facility closures and non-essential expense reductions implies a constrained financial position that may limit the ability to sustain costly clinical programs without additional dilutive financing, a risk exacerbated by the current challenging biotech financing environment. Furthermore, the CEO’s letter highlights increased engagement with capital markets and evaluation of broader opportunities, but offers no concrete timeline, financial commitment, or strategic clarity on how such repositioning would be executed or funded, leaving investors with vague promises rather than actionable plans, which could erode trust if not followed by tangible progress. The absence of any discussion regarding clinical trial updates, regulatory interactions, or manufacturing advancements in the recent communications suggests that the core scientific mission may be deprioritized in favor of financial engineering, a shift that could ultimately undermine long-term value creation if the company fails to establish credibility in its primary therapeutic area.

Despite the leadership changes and financial restructuring efforts, BiomX remains a clinical-stage company with no revenue-generating products, and the recent news provides no evidence of clinical progress, partnership advancements, or near-term milestones in its core phage therapy pipeline, meaning the company’s fundamental value still hinges on uncertain and long-distant binary outcomes from clinical trials that are highly susceptible to failure, delays, or regulatory setbacks. The emphasis on evaluating strategic opportunities in defense-related applications and engaging with Wall Street advisors suggests a potential distraction from or lack of confidence in the core business, raising concerns that management may be pivoting away from its stated mission due to insufficient progress in phage therapy development, which could signal underlying weaknesses in the BOLT platform or target validation that are not being disclosed. While the warrant amendment reduces theoretical overhang, it does not address the company’s ongoing cash burn or lack of funding visibility, and the reliance on cost-cutting measures like facility closures and non-essential expense reductions implies a constrained financial position that may limit the ability to sustain costly clinical programs without additional dilutive financing, a risk exacerbated by the current challenging biotech financing environment. Furthermore, the CEO’s letter highlights increased engagement with capital markets and evaluation of broader opportunities, but offers no concrete timeline, financial commitment, or strategic clarity on how such repositioning would be executed or funded, leaving investors with vague promises rather than actionable plans, which could erode trust if not followed by tangible progress. The absence of any discussion regarding clinical trial updates, regulatory interactions, or manufacturing advancements in the recent communications suggests that the core scientific mission may be deprioritized in favor of financial engineering, a shift that could ultimately undermine long-term value creation if the company fails to establish credibility in its primary therapeutic area.

Peer group

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AMGN	Amgen Inc	primary	211.73 Bn	24.22	5.56	62.75 Bn
2	GILD	Gilead Sciences, Inc.	primary	180.92 Bn	-62.49	5.94	28.66 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	primary	132.16 Bn	30.00	10.50	-
4	REGN	Regeneron Pharmaceuticals, Inc.	primary	82.89 Bn	19.15	5.34	1.99 Bn
5	ARGX	Argenx Se	primary	61.41 Bn	35.80	11.75	-
6	MRNA	Moderna, Inc.	primary	53.99 Bn	-17.13	24.23	0.59 Bn
7	ALNY	Alnylam Pharmaceuticals, Inc.	primary	34.48 Bn	44.51	7.18	-
8	BIIB	Biogen Inc.	primary	31.15 Bn	37.32	3.11	8.09 Bn

BiomX PHGE

About

Investment Thesis

Peer Comparison

Create an account

Sign In

Reset Password